Keysight partners with NVIDIA on quantum-AI computing architecture
Investing.com - Cantor Fitzgerald has raised its price target on Viking Therapeutics (NASDAQ:VKTX) to $105.00 from $104.00 while maintaining an Overweight rating on the stock. The new target represents significant upside from the current price of $35.64, with the broader analyst consensus also remaining strongly bullish at 1.47 (Strong Buy). According to InvestingPro data, the stock has shown impressive momentum with a 30% gain over the past six months.
The research firm described the company’s latest update as "the most bullish" since it began covering Viking more than seven years ago.
Cantor Fitzgerald highlighted that Viking has established five "critically important data catalysts" scheduled over the next 24 months, with appropriate spacing between announcements.
The company confirmed it has over $700 million in cash, which it believes is sufficient to fund operations through all upcoming milestones.
Cantor Fitzgerald expressed confidence that Viking is positioning VK2735 to prove itself as "one of the best obesity assets in biotech," with additional diversification coming from a novel DACRA compound expected in the first quarter of 2026.
In other recent news, Viking Therapeutics reported its third-quarter 2025 earnings with an earnings per share (EPS) of -$0.81. This figure missed both the consensus estimate of -$0.67 and H.C. Wainwright’s estimate of -$0.71. Despite the wider-than-expected loss, analysts at H.C. Wainwright and BTIG have reiterated their Buy ratings on the company, with price targets set at $102.00 and $125.00, respectively. Viking Therapeutics has also reported significant progress in its obesity drug portfolio, particularly with the VANQUISH study. The company is ahead of schedule in completing enrollment for the first Phase 3 study in the fourth quarter of 2025 and aims to complete the second study in the first quarter of 2026. Data readouts for these studies are expected between mid-to-late 2027. These developments come amid a challenging financial quarter but show promise in Viking’s ongoing research efforts.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.